Across TCGA pan-cancer cohorts, SIRPA mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SIRPA data layer compared with 22 for mass-spec protein and 4 for mutation status.
The strongest signal is observed in lung adenocarcinoma (LUAD), where higher SIRPA mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated SIRPA expression acts as an unfavorable survival marker, although some lineages such as UCEC and GBM show a favorable association.
LUAD, UCEC, and GBM are the cancer types where SIRPA mass-spec protein most reproducibly stratifies survival.
mass-spec protein survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.